ACAD vs CISS โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ACAD Captures Institutional Edge (2โ2 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Acadia Pharmaceuticals Inc. (ACAD) driven by superior Valuation, Options & Structure while CISS counters with relative strength in Growth & Margin, Momentum & Technical. Fundamentally, ACAD trades at 15.8x Forward P/E with 10.2% operating margin (+22.8% YoY revenue) versus CISS at N/M Forward P/E and 24.6% operating margin (+249.0% YoY). In options structure, ACAD sits in BREAKDOWN (6th %ile IV; Dealer Gamma Walls on Pro) against CISS sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ACAD Revenue | CISS Revenue | ACAD Op. Margin | CISS Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $220M | N/A | -110.6% | N/A | ACAD |
| FY2019 | $340M | N/A | -72.7% | N/A | ACAD |
| FY2020 | $440M | N/A | -64.9% | N/A | ACAD |
| FY2021 | $480M | N/A | -35.2% | N/A | ACAD |
| FY2022 | $520M | N/A | -43.2% | N/A | ACAD |
| FY2023 | $730M | $30M | -10.1% | 36.3% | CISS |
| FY2024 | $960M | $40M | 24.1% | 23.8% | ACAD |
| FY2025 | $1.07B | $30M | 9.8% | 3.9% | ACAD |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ACAD | CISS | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.0B | $991,199 | Larger Scale | ACAD |
| Trailing P/E Ratio Valuation | 8.3x | N/M | Lower Multiple | ACAD |
| Forward P/E Ratio Valuation | 15.8x | N/M | Lower Multiple | ACAD |
| Revenue Growth (YoY) Growth | +22.8% | +249.0% | Higher Growth | CISS |
| Operating Margin (TTM) Profitability | 10.2% | 24.6% | Higher Margin | CISS |
| Net Profit Margin Profitability | 30.1% | 27.4% | Higher Margin | ACAD |
| Return on Equity (ROE) Capital Efficiency | 31.4% | 17.1% | Higher ROE | ACAD |
| 52-Week Range Position Momentum | 8% ($16โ$31) | 20% ($0โ$6) | Stronger Trend | CISS |
| Beta / 30D Volatility Risk Regime | 0.15ฮฒ ยท 90% Vol | 11.91ฮฒ ยท 1054% Vol | Lower Realized Risk | ACAD |
| Unified Institutional Score Composite Signal | 44.8 / 100 (HOLD) | 33.6 / 100 (SELL) | Higher Composite | ACAD |